The present study observed markedly higher levels of both CD8+ T cells and TIL in low-risk PC patients, with additional higher levels of expression of immune checkpoints like CTLA4 and PD-1, which seems to imply that patients with low-risk could benefit more from receiving immunotherapy. Here, CTLA4 is linked to pachyonychia congenita.